Rapport Therapeutics, Inc. Form 4 Filings

Rapport Therapeutics, Inc. (RAPP) reported that Chief Executive Officer and director Abraham Ceesay sold 18,921 shares of common stock on August 25, 2026 in an open-market transaction at a weighted average price of $49.5723 per share, pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026. Following this sale, he directly holds 467,187 shares of common stock, and also has indirect ownership of 81,729 shares through the Ceesay Family Irrevocable Trust and 20,729 shares through the Dorothy Ceesay Irrevocable Trust.

Rapport Therapeutics, Inc. (RAPP) reported that Chief Development Officer Krishnaswamy Yeleswaram sold a total of 50,160 shares of common stock in open-market transactions on August 24–25, 2026. The sales were executed under a Rule 10b5-1 trading plan adopted on December 10, 2025, at weighted average prices around $50–$51 per share across multiple price ranges.

Rapport Therapeutics, Inc. (RAPP) reported that Chief Development Officer Krishnaswamy Yeleswaram sold 404 shares of common stock on 2026-08-19 at $49.90 per share in an open-market transaction. After this sale, the officer directly held 246,022 shares. The sale was made pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025.

Rapport Therapeutics, Inc. Chief Executive Officer Abraham Ceesay reported open-market sales of 51,499 shares of common stock on August 10–11, 2026, in multiple transactions at weighted average prices between about $45.97 and $48.62. The sales were effected pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026. Following these trades, indirect holdings include 81,729 shares held by the Ceesay Family Irrevocable Trust and 20,729 shares held by the Dorothy Ceesay Irrevocable Trust.

Rapport Therapeutics, Inc. Chief Executive Officer Abraham Ceesay reported selling a total of 2,210 shares of common stock on July 27, 2026, in two transactions, including 2,203 shares at a weighted average price of $42.1070 (with individual trades between $41.66 and $42.50) and 7 shares at $42.7350 per share, pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026.

Separate from these sales, 81,729 shares are held by The Ceesay Family Irrevocable Trust and 20,729 shares by The Dorothy Ceesay Irrevocable Trust; Ceesay disclaims beneficial ownership of these trust-held shares except to the extent of any pecuniary interest.

Rapport Therapeutics, Inc. Chief Executive Officer Abraham Ceesay reported open-market sales of 8,210 shares of common stock on July 14, 2026, in two transactions at weighted-average prices of $40.57 and $39.72, executed under Rule 10b5-1 trading plans adopted on March 27, 2026. Following these sales, he holds 539,817 shares directly. Additional shares are held in two irrevocable trusts (20,729 and 81,729 shares), for which he disclaims beneficial ownership except to the extent of any pecuniary interest.

Rapport Therapeutics Chief Operating Officer Cheryl Gault reported open-market sales totaling 10,000 shares of common stock on June 30, 2026. The transactions were carried out under a pre-arranged Rule 10b5-1 trading plan at weighted average prices between about $40 and $43 per share.

Rapport Therapeutics, Inc. Chief Executive Officer Abraham Ceesay reported open-market sales of common stock under pre-arranged Rule 10b5-1 trading plans adopted on March 27, 2026. He sold 8,220 shares on June 29, 2026 in two transactions at weighted average prices of $39.77 and $40.34 per share.

Following these sales, Ceesay held 548,027 shares of common stock directly. Additional shares are held indirectly by The Ceesay Family Irrevocable Trust and The Dorothy Ceesay Irrevocable Trust, for which he disclaims beneficial ownership except to any pecuniary interest.

Rapport Therapeutics, Inc. director John Maraganore received a grant of stock options covering 15,200 shares of common stock. The options have an exercise price of $35.21 per share and expire on June 10, 2036. Following this award, he holds 15,200 options directly.

The options vest upon the earlier of June 10, 2027 or the date of the next Annual Meeting of Stockholders, subject to his continued service on that vesting date. This is a compensation-related award rather than an open-market purchase or sale.

Rapport Therapeutics director Robert J. Perez received a grant of stock options for 15,200 shares of common stock. The options have an exercise price of $35.21 per share and expire on June 10, 2036.

The shares underlying this option vest upon the earlier of June 10, 2027 or the date of the next Annual Meeting of Stockholders of Rapport Therapeutics, subject to his continued service on that vesting date. Following this grant, he holds 15,200 derivative securities directly.

Rapport Therapeutics, Inc. director Steven M. Paul received a grant of stock options covering 15,200 shares of common stock. The options carry an exercise price of $35.21 per share and expire on June 10, 2036.

According to the terms, the 15,200 underlying shares will vest on the earlier of June 10, 2027 or the date of the company’s next annual meeting of stockholders, provided he continues to serve through that vesting date. Following this grant, he holds 15,200 stock options directly.

Rapport Therapeutics director Paul M. Silva received a grant of stock options as equity compensation. The award covers 15,200 options to buy common stock at an exercise price of $35.21 per share, expiring on June 10, 2036. These options vest on the earlier of June 10, 2027 or the next Annual Meeting of Stockholders, subject to his continued service.

Rapport Therapeutics director James Healy received a grant of stock options covering 15,200 shares of common stock. The options have an exercise price of $35.21 per share and expire on June 10, 2036.

The 15,200 underlying shares vest on the earlier of June 10, 2027 or the date of Rapport Therapeutics' next Annual Meeting of Stockholders, as long as Healy continues serving the company through that vesting date. After this award, he holds 15,200 derivative securities from this grant.

Rapport Therapeutics, Inc. director Reid M. Huber received a grant of stock options covering 15,200 shares of common stock. The options have an exercise price of $35.21 per share and expire on June 10, 2036. These options vest on the earlier of June 10, 2027 or the next Annual Meeting of Stockholders, subject to his continued service.

Rapport Therapeutics director Wendy B. Young received a grant of stock options covering 15,200 shares of Common Stock. The options have an exercise price of $35.21 per share and expire on June 10, 2036. Following this award, she holds 15,200 options directly.

The 15,200 underlying shares will vest on the earlier of June 10, 2027 or the date of Rapport Therapeutics’ next Annual Meeting of Stockholders, as long as she continues to serve with the company through that vesting date.

Rapport Therapeutics director Ramiro Sanchez received a grant of stock options covering 15,200 shares of Common Stock of Rapport Therapeutics, Inc. The options have an exercise price of $35.21 per share and expire on June 10, 2036.

The 15,200 option shares vest on the earlier of June 10, 2027 or the date of the next Annual Meeting of Stockholders, subject to Sanchez’s continued service. Following this award, he holds 15,200 derivative securities directly.

Third Rock Ventures funds reported a small sale of Rapport Therapeutics stock. Third Rock Ventures V, L.P. sold 18,572 shares of Rapport Therapeutics, Inc. common stock on May 26, 2026 in open-market transactions at a weighted average price of $40.047 per share, under a pre-arranged Rule 10b5-1 trading plan dated November 21, 2025.

After the sale, Third Rock Ventures V, L.P. directly held 6,280,525 shares of common stock. A related fund, Third Rock Ventures VI, L.P., is reported with 969,218 shares held indirectly, reflecting a continuing, sizeable ownership position across these affiliated investment entities.

Third Rock Ventures V, L.P. reported an open-market sale of 133,618 shares of Rapport Therapeutics, Inc. common stock on May 11, 2026 at a weighted average price of $40.244 per share. The sale occurred in multiple trades between $40.00 and $40.665 per share under a previously adopted Rule 10b5-1 trading plan.

After this transaction, Third Rock Ventures V directly held 6,299,097 shares of Rapport Therapeutics common stock. A related fund, Third Rock Ventures VI, L.P., is reported as holding an additional 969,218 shares indirectly, with the general partner entities disclaiming beneficial ownership except to the extent of any pecuniary interest.

Rapport Therapeutics, Inc. significant shareholder entities affiliated with Third Rock Ventures reported open-market sales of common stock. Third Rock Ventures V, L.P. sold 271,495 shares on May 7, 2026 at a weighted average price of $40.1210 per share and 5,018 shares on May 8, 2026 at a weighted average price of $40.3060 per share, totaling 276,513 shares sold. These transactions were executed under a previously adopted Rule 10b5-1 trading plan. After the sales, the reporting entities hold 6,432,715 shares directly through Third Rock Ventures V, L.P. and 969,218 shares indirectly through Third Rock Ventures VI, L.P., indicating a large remaining position.

Rapport Therapeutics, Inc. insider entities affiliated with Third Rock Ventures reported an open‑market sale of 426,005 shares of common stock at a weighted average price of $40.317 per share. After the sale, one reporting holder retained 6,709,228 shares directly, while another related fund held 969,218 shares indirectly. The sale was carried out under a pre‑arranged Rule 10b5‑1 trading plan dated November 21, 2025.

Rapport Therapeutics Chief Development Officer sells shares under pre-planned program. Yeleswaram Krishnaswamy completed an open-market sale of 20,225 shares of Rapport Therapeutics common stock at a weighted average price of $39.9923 per share. After the sale, he directly holds 246,426 shares. The transaction was executed under a Rule 10b5-1 trading plan adopted on December 10, 2025, indicating it was pre-scheduled rather than a discretionary trade.

Rapport Therapeutics Chief Development Officer Yeleswaram Krishnaswamy sold 19,865 shares of common stock in open-market transactions. The sales occurred on April 10, 13, and 14, 2026 at weighted average prices of $34.98, $34.97, and $35.08 per share, respectively. According to the filing, these trades were executed under a Rule 10b5-1 trading plan adopted on December 10, 2025, indicating they were pre-scheduled. Following the last sale, he continues to directly own 266,651 shares of Rapport Therapeutics common stock.

Rapport Therapeutics, Inc. Chief Development Officer Yeleswaram Krishnaswamy sold 360 shares of Common Stock in an open-market transaction at $34.90 per share on April 8, 2026.

After this sale, he directly holds 286,516 shares of Rapport Therapeutics Common Stock. The transaction was executed under a Rule 10b5-1 trading plan adopted on December 10, 2025, indicating it was pre-arranged.

Rapport Therapeutics, Inc. Chief Operating Officer Cheryl Gault reported selling a total of 10,000 shares of Common Stock in open-market transactions. She sold 7,161 shares at a weighted average price of $28.0401 and 2,839 shares at a weighted average price of $28.5530. After these sales, she directly holds 159,914 shares. The transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 10, 2025, indicating the sales were scheduled in advance rather than timed discretionarily.

Rapport Therapeutics, Inc. Chief Development Officer Yeleswaram Krishnaswamy sold 10,115 shares of common stock in an open-market transaction at a weighted average price of $29.9906 per share. The shares were sold in multiple trades between $29.90 and $30.18.

After this sale, Krishnaswamy directly holds 286,876 shares of Rapport Therapeutics common stock. The transaction was executed pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on December 10, 2025, indicating the sale was scheduled in advance.

Rapport Therapeutics, Inc. Chief Operating Officer Cheryl Gault reported an open-market sale of 2,014 shares of common stock at a weighted average price of $28.93 per share. According to the filing, the shares were sold solely to satisfy taxes from the vesting of a previously granted restricted stock unit award and did not represent a discretionary trade. After this transaction, she directly holds 169,914 shares of common stock. The sales occurred in multiple trades at prices ranging from $28.34 to $28.94.

Rapport Therapeutics Chief Executive Officer Abraham Ceesay reported open-market sales of a total of 10,916 shares of common stock on February 18 under pre-arranged Rule 10b5-1 trading plans. He sold 5,833 shares held directly, at weighted average prices of $29.0516 and $29.7983 per share. An additional 5,083 shares were sold by The Dorothy Ceesay Irrevocable Trust, also at weighted average prices around $29 per share, with Ceesay disclaiming beneficial ownership except for any pecuniary interest. After these transactions, he holds 556,247 shares directly, while trusts associated with him hold 20,729 and 81,729 shares, respectively.

Rapport Therapeutics Chief Scientific Officer David Bredt reported a mix of option exercises and share sales in company stock. On February 19, 2026, he exercised stock options for 6,000 shares at $1.80 per share, acquiring an equal number of common shares through a cash exercise.

Earlier, on February 17, 2026, he sold a total of 8,500 shares of common stock in open-market transactions at weighted average prices of $28.0211, $28.9497, and $29.5944, under a pre-arranged Rule 10b5-1 trading plan adopted on December 12, 2024. Following these transactions, he directly holds 387,075 shares of common stock and 88,080 stock options.

Rapport Therapeutics reported that Chief Medical Officer Jeffrey Sevigny received a grant of stock options on February 2, 2026. The award covers 130,000 stock options to purchase common stock at an exercise price of $27.75 per share, expiring on February 2, 2036.

The options vest in 48 equal monthly installments starting after January 1, 2026, and require Dr. Sevigny’s continued service on each vesting date. After this grant, he beneficially owns 130,000 derivative securities directly.

Rapport Therapeutics CEO Abraham Ceesay received a new stock option grant covering 428,000 shares of common stock. The option has an exercise price of $27.75 per share and was awarded on February 2, 2026. It was reported as a direct holding.

The shares underlying this option vest in forty-eight equal monthly installments following January 1, 2026, conditioned on Ceesay’s continued service with the company on each vesting date. After this grant, he beneficially owned 428,000 derivative securities in the form of stock options.

Rapport Therapeutics reported that its Chief Financial Officer, Troy Ignelzi, received a new stock option award. On February 2, 2026, he was granted an option to buy 148,000 shares of common stock at an exercise price of $27.75 per share. The option vests in 48 equal monthly installments following January 1, 2026, as long as he continues in service on each vesting date, and is scheduled to expire on February 2, 2036. After this grant, he directly beneficially owns 148,000 derivative securities in the form of this option.

Rapport Therapeutics reported that Chief Development Officer Yeleswaram Krishnaswamy received a stock option award. The option gives the right to buy 120,000 shares of common stock at an exercise price of $27.75 per share and expires on February 2, 2036.

The option was granted on February 2, 2026 and vests in 48 equal monthly installments following January 1, 2026, as long as Krishnaswamy continues in service on each vesting date. After this grant, he beneficially owns options for 120,000 shares, held directly.

Rapport Therapeutics Chief Scientific Officer granted 103,000 stock options. The Form 4 shows that officer David Bredt received a stock option covering 103,000 shares of common stock at an exercise price of $27.75 per share on February 2, 2026.

The option vests in forty-eight equal monthly installments following January 1, 2026, contingent on his continued service with the company on each vesting date. The option is scheduled to expire on February 2, 2036 if not exercised.

Rapport Therapeutics, Inc. reported that Chief Operating Officer Cheryl Gault received a stock option grant for 132,000 shares of common stock on February 2, 2026, with an exercise price of $27.75 per share and expiration on February 2, 2036.

The option vests in forty-eight equal monthly installments starting after January 1, 2026, conditioned on her continued service with the company. Following this grant, she beneficially owns 132,000 derivative securities directly.

Rapport Therapeutics Chief Executive Officer Abraham Ceesay, who is also a director, reported planned sales of company stock. On January 20, 2026, he sold 5,833 shares of common stock directly at a weighted average price of $26.1158, leaving him with 562,080 directly held shares.

On the same date, 5,083 shares of Rapport common stock were sold at a weighted average price of $26.114 by The Dorothy Ceesay Irrevocable Trust, which now holds 25,812 shares, and a separate Ceesay Family Irrevocable Trust holds 81,729 shares. All reported sales were made under Rule 10b5-1 trading plans adopted on December 12, 2024. The trusts are associated with Ceesay, but he disclaims beneficial ownership of their shares except to the extent of any pecuniary interest.

Rapport Therapeutics Chief Scientific Officer David Bredt reported selling common stock in the company. On January 15, 2026, he sold 8,300 shares of common stock at a weighted average price of $26.8255 and an additional 200 shares at $27.40. The weighted average sale was executed in multiple trades at prices ranging from $26.33 to $27.30. After these sales, Bredt beneficially owned 395,575 shares of common stock directly. The filing notes that these transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 12, 2024, which is designed to allow insiders to sell shares according to a preset schedule.

Rapport Therapeutics, Inc. reported insider share sales by its chief executive officer and director on December 17, 2025, executed under Rule 10b5-1 trading plans adopted on December 12, 2024. The reporting person sold several blocks of common stock, including 2,441 shares at a weighted average price of $28.8378, 2,792 shares at $30.0365, and 600 shares at $31.036, with additional sales through an irrevocable trust at weighted average prices between roughly $28.84 and $31.04 per share, as disclosed in the footnotes.

Following these transactions, the reporting person beneficially owns 567,913 shares of common stock directly, and indirectly holds 30,895 shares through The Dorothy Ceesay Irrevocable Trust and 81,729 shares through The Ceesay Family Irrevocable Trust. The filing states that beneficial ownership of the trust-held shares is disclaimed except to the extent of any pecuniary interest.

Rapport Therapeutics, Inc. reported that its Chief Scientific Officer, who is an officer of the company, sold common stock on 12/15/2025. The transactions involved sales of 7,704 shares at a weighted average price of $29.9469 and 796 shares at a weighted average price of $30.6772, both coded as open-market sales.

These sales were made pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024. Following the reported transactions, the officer directly beneficially owns 392,642 shares of Rapport Therapeutics common stock.

Rapport Therapeutics, Inc. (RAPP) reported insider stock sales by its Chief Executive Officer and director on a Form 4. On 11/17/2025, the reporting person sold 2,777, 3,056, 2,242 and 2,841 shares of common stock in multiple transactions at weighted average prices of $24.9246, $25.4303, $24.9107 and $25.437, respectively. The filing states these trades were made under Rule 10b5-1 trading plans adopted on December 12, 2024. Following the transactions, the reporting person directly owns 573,746 shares and has additional indirect holdings through the Dorothy Ceesay Irrevocable Trust and the Ceesay Family Irrevocable Trust, while disclaiming beneficial ownership of those trust shares except for any pecuniary interest.

Rapport Therapeutics, Inc. (RAPP) reported an insider stock sale by an executive officer. The reporting person, who serves as Chief Scientific Officer, filed a Form 4 showing two open-market sales of common stock on 11/17/2025.

The executive sold 3,156 shares of common stock at a weighted average price of $24.8399, followed by an additional 5,344 shares at a weighted average price of $25.3922. After these transactions, the officer beneficially owns 401,142 shares of Rapport Therapeutics common stock in direct ownership form.

The filing explains that these transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 12, 2024, which is designed to allow insiders to sell shares according to predetermined instructions.

Rapport Therapeutics (RAPP) — insider trading report: On 10/15/2025, the company’s Chief Executive Officer and Director executed multiple open‑market sales under Rule 10b5‑1 trading plans adopted on December 12, 2024. Reported transactions included 4,647 shares at a weighted average price of $25.724 and 1,186 shares at $26.1392. Trust-related sales included 4,328 shares at $25.746 and 755 shares at $26.1721.

After these transactions, the reporting person beneficially owned 579,579 shares directly. Indirect holdings reported were 41,061 shares held by the Dorothy Ceesay Irrevocable Trust and 81,729 shares held by the Ceesay Family Irrevocable Trust.

Rapport Therapeutics (RAPP): Form 4 insider sale. On 10/15/2025, the Chief Scientific Officer sold 7,418 shares at a weighted average price of $25.7329 and 1,082 shares at a weighted average price of $26.1641. Sales occurred in multiple trades within disclosed ranges.

Following these transactions, the officer directly holds 409,642 shares. The trades were executed pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024.

Ceesay Abraham, who is listed as both Chief Executive Officer and a director of Rapport Therapeutics, Inc. (RAPP), reported multiple dispositions of the company’s common stock on 09/17/2025. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024. The Form 4 lists four disposition entries: 39,435 shares at a weighted-average price of $26.299, 1,400 shares at $26.8745, 34,885 shares at $26.3019 and 700 shares at $27.0429. The filing shows resulting beneficial ownership figures on each line, including direct holdings of 585,412 and 586,812 shares on certain lines and indirect holdings held by the Dorothy Ceesay Irrevocable Trust and the Ceesay Family Irrevocable Trust (listed as 46,844 I, 46,144 I and 81,729 I). Explanatory notes disclose price ranges for the multiple transactions and that the reporting person disclaims beneficial ownership of trust-held shares except to the extent of any pecuniary interest.

Rapport Therapeutics, Inc. reported that Chief Scientific Officer David Bredt sold a total of 8,500 shares of common stock on September 15, 2025, in open-market or private transactions under a Rule 10b5-1 trading plan adopted on December 12, 2024. The sales were executed at weighted-average prices of $23.8841 and $24.6583 per share across multiple trades at prices ranging from $23.42 to $24.41 and from $24.42 to $24.90. Following these sales, Bredt held 418,142 shares of common stock directly.